CD74 antibody
Quick Overview for CD74 antibody (ABIN6297713)
Target
See all CD74 AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Purpose
- Mouse anti-Human CD74 Antibody Cocktail [IHC only]
-
Specificity
- Cell surface and paranuclear globular
-
Purification
- SU-DHL-4 lymphoma cells (LN-2) and recombinant full-length human protein (CLIP/813) were used as the immunogen for the CD74 antibody cocktail.
-
Immunogen
- SU-DHL-4 lymphoma cells (LN-2) and recombinant full-length human protein (CLIP/813) were used as the immunogen for the CD74 antibody cocktail.
-
-
-
-
Application Notes
- Prediluted format : incubate for 30 min at RT (2)
-
Restrictions
- For Research Use only
-
-
-
Buffer
- Prediluted in 1X PBS with 0.1 mg/mL BSA (US sourced) and 0.05 % sodium azide, For IHC use only
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Storage
- 4 °C,-20 °C
-
Storage Comment
- 2-8°C. The azide-free format should be aliquoted and stored at -20°C or colder.
-
-
- CD74 (HLA-DR-gamma (CD74))
-
Alternative Name
- HLA class II histocompatibility antigen gamma chain
-
Background
-
Target Description: It recognizes a protein of ~35 kDa, identified as CD74/CLIP. It is a type II transmembrane protein which binds to the peptide binding groove of newly synthesized MHC class II alpha/beta heterodimers and prevents their premature association with endogenous polypeptides. CD74 is expressed primarily by antigen presenting cells, such as B-lymphocytes (from before the pre-B cell stage to before the plasma cell stage), macrophages, and monocytes, and many epithelial cells. Anti-CD74 stains predominantly germinal center lymphocytes and B-cell lymphomas, but rarely T-cell lymphomas. Anti-CD74 has been shown to be useful in differentiating atypical fibroxanthoma (-) from malignant fibrous histiocytoma (+).
Gene Symbol: CD74///DHLAG
-
Gene ID
- 296
-
UniProt
- P04233
-
Pathways
- Positive Regulation of Immune Effector Process, Production of Molecular Mediator of Immune Response, Negative Regulation of intrinsic apoptotic Signaling, Cancer Immune Checkpoints
Target
-